Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest

BMC Molecular Biology

Volumn 11, Issue , 2010, Pages

  Koprinarova, Miglena ^a   Markovska, Petya ^a   Iliev, Ivan ^b   Anachkova, Boyka ^a   Russev, George ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Bulgaria)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CISPLATIN; HISTONE H4; ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; EHRLICH ASCITES TUMOR; EUCHROMATIN; HELA CELL; HETEROCHROMATIN; HUMAN; HUMAN CELL; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; ACYLATION; ANIMAL; CELL CYCLE; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM;

MUS;

ACYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BUTYRATES; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; CISPLATIN; G1 PHASE; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MICE; MICE, INBRED ICR; S PHASE;

EID: 77954852413     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-11-49     Document Type: Article

References (36)

1. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP. Histone deacetylase inhibitors have profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004, 10:1141-9. 10.1158/1078-0432.CCR-03-0100, 14871994.
2. Taddei A, Roche D, Bickmore WA, Almouzni G. The effect of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?. EMBO Rep 2005, 6:520-4. 10.1038/sj.embor.7400441, 1369099, 15940285.
3. Smith KT, Workman J. Histone deacetylase inhibitors: Anticancer compounds. Int J Biochem & Cell Biol 2009, 41:21-25.
4. Wang D, Wang Z, Tian B, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer cells to anticancer drugs. Int J Urol 2008, 15:435-41. 10.1111/j.1442-2042.2008.02025.x, 18452462.
5. Lee SK, Kim SB, Kim SS, Moon CH, Han MS, Lee BS, Chung DK, Min JP, Park JH, Choi DH, Cho HR, Park SK, Park JW. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int J Cancer 2005, 117:32-40. 10.1002/ijc.21133, 15880358.
6. Sato T, Suzuki M, Sato Y, Echigo S, Rikishi H. Sequence dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006, 28:1233-41.
7. Mühlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM, Gross N. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumor activity in neuroblastoma cells. BMC Mol Cancer 2008, 7:55.
8. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJF, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenish R, Tsai LH. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 7243:55-60.
9. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanism of action. Oncogene 2007, 26:5541-52. 10.1038/sj.onc.1210620, 17694093.
10. Li RW, Li C. Butyrate induces profound changes in gene expression related to multiple single pathways in bovine kidney epithelial cells. BMC Genomics 2006, 7:234. 10.1186/1471-2164-7-234, 1592091, 16972989.
11. Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol 2006, 25:49-62. 10.1089/dna.2006.25.49, 16405400.
12. Dokmanovic M, Clarke K, Marks P. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007, 5:981-989. 10.1158/1541-7786.MCR-07-0324, 17951399.
13. Ruiz-Garrillo A, Wangh LJ, Allfrey VG. Processing of newly synthesized histone molecules. Science 1975, 190:117-28. 10.1126/science.1166303, 1166303.
14. Benson L, Gu Y, Yakovleva T, Tong K, Barrows C, Stark CL, Cook RG, Mizzen CA, Annunziato A. Modification of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange. J Biol Chem 2006, 281:9287-96. 10.1074/jbc.M512956200, 16464854.
15. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nature/reviews/ 2007, 8:284-94.
16. Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover?. Biochim Cell Biol 2002, 80:363-78.
17. Kemp MG, Ghosh M, Liu G, Leffak M. The histone deacetylase inhibitor trichostatin A alters the pattern of DNA replication origin activity in human cells. Nucl Acid Res 2005, 33:325-36.
18. Koprinarova M, Russev G. Dynamics of histone H4 acetylation during the cell cycle. Cell Cycle 2008, 7:414-6.
19. Koprinarova M, Russev G. Histone H4 acetylation during UV light induced G1 and S phase arrest of cell cycle. Cell Cycle 2008, 7:1496-8.
20. Katan-Khayakovich Y, Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev 2002, 16:743-52. 10.1101/gad.967302, 155357, 11914279.
21. Wu JT, Archer SY, Hinnebusch B, Meng S, Hodin RA. Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation and apoptosis. Am J Physiol Gastrointest Liver Physiol 2001, 280:G482-90.
22. Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem Biol Ineract 2004, 148:37-48.
23. Belakavadi M, Prabhakar BT, Salimath BP. Butyrate-induced proapoptotic and antiangiogenic pathways in EAT cells require activation of CAD and downregulation of VEGF. Biochem Biophys Res Commun 2005, 335:993-1001. 10.1016/j.bbrc.2005.07.172, 16105646.
24. Pal S, Sadhu AS, Patra S, Mukherjea KK. Histological vis-à-vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on experimental animal models. J Exp Clin Cancer Res 2008, 12:27-68.
25. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 1998, 95:4219-23. 10.1073/pnas.95.8.4219, 22469, 9539717.
26. Un F. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers. Anticancer Drugs 2007, 18:411-7. 10.1097/CAD.0b013e32801429ed, 17351393.
27. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Arnow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response to breast cancer. J Clin Invest 2007, 117:218-28. 10.1172/JCI28803, 1679964, 17160137.
28. Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res 2007, 67:8264-73. 10.1158/0008-5472.CAN-06-4753, 17804741.
29. Abramova MV, Pospelova TV, Nikulenkov FP, Hollander CM, Fornace AJ, Pospelov VA. G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A+Ras transformed cells is mediated through down-regulation of E2F activity and stabilization of β-catenin. J Biol Chem 2006, 281:0-51.
30. Li CJ, Elsasser TH. Butyrate induced apoptosis and cell cycle arrest in bovine kidney epithelial cells: Involvement of caspase and proteasome pathways. J Animal Sci 2005, 83:89-97.
31. Tsvetkov L, Russev G. Decreased rates of replicon initiation in mammalian cells. Eur J Biochem 1996, 237:489-495. 10.1111/j.1432-1033.1996.0489k.x, 8647090.
32. Fathallah H, Portonoy G, Atweh GF. Epigenetic analysis of human alpha- and beta-globin gene clusters. Blood Cells Mol Dis 2008, 40:166-73. 10.1016/j.bcmd.2007.08.001, 2270787, 18029204.
33. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478:23-43.
34. Jack MT, Woo RA, Hirao A, Cheung A, Mark TW, Lee PW. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 2002, 99:9825-9. 10.1073/pnas.152053599, 125030, 12097646.
35. Carrassa L, Broggini M, Erba E, Damis G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004, 3:1177-81.
36. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential role of checkpoint kinase 1 checkpoint kinase 2 and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implication for cancer therapy. Mol Cancer Ther 2006, 5:1935-43. 10.1158/1535-7163.MCT-06-0077, 16928813.